IMC Chicago’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-33,000
Closed -$715K 2478
2023
Q4
$715K Sell
33,000
-1,300
-4% -$25.8K ﹤0.01% 1543
2023
Q3
$706K Buy
+34,300
New +$991K ﹤0.01% 1342
2021
Q1
Sell
-15,200
Closed -$1.31M 1164
2020
Q4
$1.31M Sell
15,200
-8,600
-36% -$634K ﹤0.01% 802
2020
Q3
$1.46M Buy
+23,800
New +$1.21M ﹤0.01% 647
2020
Q1
Sell
-22,500
Closed -$1.62M 893
2019
Q4
$1.62M Buy
+22,500
New +$2.77M ﹤0.01% 556
2019
Q1
Sell
-7,500
Closed -$718K 853
2018
Q4
$718K Buy
+7,500
New +$858K ﹤0.01% 521

Other funds holding SAGE

IMC Chicago's SAGE Position: Q1 2019 in Review

IMC Chicago sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 4,212 shares — an estimated $403K sold.

IMC Chicago first reported a position in SAGE in Q4 2018 and held it in 1 quarter. The position peaked at $403K in Q4 2018. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

  • IMC Chicago reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
  • IMC Chicago sold 4,212 Sage Therapeutics shares in Q1 2019, an estimated $403K.
  • IMC Chicago first reported a position in Sage Therapeutics in Q4 2018 and held it in 1 quarter.
  • IMC Chicago's Sage Therapeutics position peaked at $403K in Q4 2018.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on IMC Chicago's 13F filing for Q1 2019, filed 15 May 2019.